Neurocrine Biosciences, Inc. $NBIX Shares Bought by American Century Companies Inc.

American Century Companies Inc. boosted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 106.6% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 191,182 shares of the company’s stock after acquiring an additional 98,659 shares during the period. American Century Companies Inc. owned about 0.19% of Neurocrine Biosciences worth $21,145,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NBIX. Smallwood Wealth Investment Management LLC acquired a new stake in Neurocrine Biosciences during the 1st quarter worth $34,000. GeoWealth Management LLC boosted its stake in Neurocrine Biosciences by 65.4% during the 4th quarter. GeoWealth Management LLC now owns 258 shares of the company’s stock worth $35,000 after purchasing an additional 102 shares during the last quarter. Golden State Wealth Management LLC boosted its stake in Neurocrine Biosciences by 116.9% during the 1st quarter. Golden State Wealth Management LLC now owns 397 shares of the company’s stock worth $44,000 after purchasing an additional 214 shares during the last quarter. Versant Capital Management Inc boosted its stake in Neurocrine Biosciences by 404.9% during the 1st quarter. Versant Capital Management Inc now owns 409 shares of the company’s stock worth $45,000 after purchasing an additional 328 shares during the last quarter. Finally, Harbor Capital Advisors Inc. acquired a new stake in Neurocrine Biosciences during the 1st quarter worth $48,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Buying and Selling

In related news, insider Ingrid Delaet sold 457 shares of the business’s stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $135.00, for a total value of $61,695.00. Following the sale, the insider owned 4,730 shares in the company, valued at approximately $638,550. The trade was a 8.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jude Onyia sold 59,819 shares of the stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $130.46, for a total value of $7,803,986.74. Following the transaction, the insider directly owned 18,289 shares in the company, valued at approximately $2,385,982.94. The trade was a 76.58% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 196,573 shares of company stock valued at $25,112,766. 4.80% of the stock is currently owned by insiders.

Neurocrine Biosciences Trading Up 0.1%

Shares of NASDAQ:NBIX opened at $135.43 on Friday. The business has a 50-day moving average price of $130.13 and a 200 day moving average price of $119.00. The company has a market capitalization of $13.43 billion, a price-to-earnings ratio of 40.07, a PEG ratio of 0.98 and a beta of 0.25. Neurocrine Biosciences, Inc. has a 12-month low of $84.23 and a 12-month high of $154.87.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.08. The firm had revenue of $687.50 million during the quarter, compared to the consensus estimate of $653.09 million. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%.The company’s quarterly revenue was up 16.5% on a year-over-year basis. During the same period last year, the company earned $1.63 EPS. As a group, equities research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NBIX has been the topic of several recent research reports. Needham & Company LLC lifted their target price on shares of Neurocrine Biosciences from $138.00 to $139.00 and gave the stock a “buy” rating in a research note on Tuesday, May 6th. Truist Financial assumed coverage on Neurocrine Biosciences in a research note on Monday, July 21st. They issued a “buy” rating and a $163.00 target price for the company. Royal Bank Of Canada cut their target price on Neurocrine Biosciences from $146.00 to $144.00 and set an “outperform” rating for the company in a research note on Thursday, July 31st. JPMorgan Chase & Co. boosted their price target on shares of Neurocrine Biosciences from $140.00 to $145.00 and gave the company a “neutral” rating in a research report on Thursday, July 31st. Finally, Wall Street Zen raised shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 2nd. Eighteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $159.50.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.